Follow this preprint
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
View ORCID ProfilePhillip L.R. Nicolson, Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Steve P. Watson, Gillian C. Lowe, William A. Lester
doi: https://doi.org/10.1101/2021.08.17.21262138
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Phillip L.R. Nicolson
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
MD, PhDSamantha J. Montague
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
PhDChristopher W. Smith
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
PhDClare S. Lodwick
3Department of Haematology, Worcester Acute Hospitals NHS Trust, Worcester WR5 1DD, UK
MDCharlotte Stoneley
4Department of Blood Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
MScMatthew Roberts
4Department of Blood Sciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, UK
MScSteve P. Watson
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK
PhDGillian C. Lowe
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
MD PhDWilliam A. Lester
2Comprehensive Care Haemophilia Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK
MD, PhD![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
Individual participant data will not be made available.
Posted August 23, 2021.
Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination
Phillip L.R. Nicolson, Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Steve P. Watson, Gillian C. Lowe, William A. Lester
medRxiv 2021.08.17.21262138; doi: https://doi.org/10.1101/2021.08.17.21262138
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Subject Areas
- Addiction Medicine (408)
- Allergy and Immunology (720)
- Anesthesia (214)
- Cardiovascular Medicine (3042)
- Dermatology (258)
- Emergency Medicine (456)
- Epidemiology (12963)
- Forensic Medicine (12)
- Gastroenterology (848)
- Genetic and Genomic Medicine (4773)
- Geriatric Medicine (441)
- Health Economics (747)
- Health Informatics (3029)
- Health Policy (1096)
- Hematology (405)
- HIV/AIDS (952)
- Medical Education (450)
- Medical Ethics (119)
- Nephrology (490)
- Neurology (4545)
- Nursing (242)
- Nutrition (671)
- Oncology (2365)
- Ophthalmology (666)
- Orthopedics (264)
- Otolaryngology (332)
- Pain Medicine (296)
- Palliative Medicine (86)
- Pathology (512)
- Pediatrics (1232)
- Primary Care Research (515)
- Public and Global Health (7136)
- Radiology and Imaging (1587)
- Respiratory Medicine (940)
- Rheumatology (456)
- Sports Medicine (396)
- Surgery (505)
- Toxicology (63)
- Transplantation (218)
- Urology (187)